Alle Studien
RekrutierungPHASE3INTERVENTIONELL

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

This research study is for people with advanced neuroendocrine tumours of the gut or pancreas (GEP-NETs) that have spread or can't be removed, and that are found to have a specific marker (Somatostatin Receptor Positive). The study is testing a new treatment called [177Lu]Lu-DOTA-TATE, given alongside a standard medicine called Octreotide LAR. This combination will be compared to receiving Octreotide LAR on its own. Researchers want to see if the new combination is better at controlling the cancer and if it's safe for patients. Participants must be at least 12 years old and have been recently diagnosed with this type of cancer, with what doctors call a 'high disease burden'.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Novartis Pharma
Einschreibeziel
240
Starten
30. Mai 2025
Geschätzte Fertigstellung
23 Jan 2034

Worum geht es in dieser Studie?

This study is designed to help us learn more about a type of cancer called Gastroenteropancreatic Neuroendocrine Tumours, or GEP-NETs for short. These are uncommon cancers that can grow in the gut or pancreas. When these cancers are advanced, it means they might have spread to other parts of the body or are in a place that makes them hard to remove with surgery. The main goal of this study is to test a new treatment to see if it can help patients with this advanced condition.

The new treatment involves a medicine called [177Lu]Lu-DOTA-TATE, which is given together with an existing medicine called Octreotide LAR. Octreotide LAR is already used to treat GEP-NETs. The study will compare patients who receive both the new medicine and Octreotide LAR, to patients who just receive Octreotide LAR. We want to find out if combining these treatments is more effective at controlling the cancer and whether it's safe for people to take.

Taking part in a study like this helps doctors understand new ways to treat diseases. By comparing the usual treatment with a new one, researchers can see if the new approach is better for patients now and in the future. This kind of research is very important for improving care for people living with GEP-NETs.

Wichtige Erkenntnisse

  • This study is for advanced gut or pancreatic neuroendocrine tumours (GEP-NETs).
  • It tests a new medicine combination against a standard treatment.
  • Participants must be at least 12 years old.
  • The study aims to see if the new treatment is safe and more effective.
  • Your health will be closely watched throughout the study.
  • Sie können jederzeit von der Studie zurücktreten.

Wer könnte berechtigt sein?

This study is looking for people who have been diagnosed with a specific type of advanced neuroendocrine tumour affecting the gut or pancreas (GEP-NETs). The cancer needs to be well-understood by doctors, with a recent diagnosis (within the last six months) and it shouldn't be possible to cure with surgery. Participants must also have specific markers on their cancer, which doctors can check with special scans.

To join, you need to be at least 12 years old. Doctors will consider if your cancer has a 'high disease burden'. This could mean the main tumour or a tumour that has spread is bigger than 4cm, or there are several tumours larger than 2cm. Other signs of high disease burden include changes in certain blood tests, cancer in your bones or the lining of your belly, or if the cancer is causing bothersome symptoms like pain, tiredness, or weight loss.

Before you start, doctors will also check your general health, including your blood counts and how well your kidneys and liver are working. These checks are important to make sure it's safe for you to take part in the study medicines.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Have I been diagnosed with an advanced GEP-NET within the last 6 months?
  2. Do doctors think my cancer has a 'high disease burden' (e.g., larger tumours, affecting bones)?
  3. Am I 12 years old or older?
  4. Have scans shown my tumour has specific 'somatostatin receptors'?
  5. Are my blood tests, kidney, and liver functions generally healthy enough for the study?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study will involve several stages. First, there's a 'screening phase' where doctors will do various tests and scans to make sure you meet all the requirements for the study. This might include blood tests and special scans to look at your tumour.

If you're eligible, you'll then enter the 'treatment phase'. During this time, you'll receive either the new combination treatment or Octreotide LAR on its own. You'll have regular visits to the clinic for your treatments, check-ups, blood tests, and scans. The medical team will keep a close eye on you to see how you're responding to the treatment and to check for any side effects.

After your treatment is complete, there will be a 'follow-up phase'. This means you'll continue to have check-ups for a period of time to monitor your health and long-term effects of the treatment. The total length of time you'll be involved in the study, from your first screening appointment to your last follow-up, will depend on the study plan, but it generally lasts for a number of years.

Potenzielle Risiken und Vorteile

Taking part in a clinical study can have both potential benefits and risks. You might benefit from receiving a new treatment that isn't yet widely available, and your health will be closely monitored by a team of experts. However, there's no guarantee the new treatment will work for you, and it might have side effects that aren't fully known yet. You also might receive the standard treatment only, depending on what group you are in. All medical treatments carry some risks, and the study team will explain these to you in detail. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (67)

  • Mayo Clinic Arizona
    Verifizierte Postleitzahl
    Scottsdale, Vereinigte Staaten· Rekrutierung
  • Highlands Oncology Group
    Verifizierte Postleitzahl
    Fayetteville, Vereinigte Staaten· Rekrutierung
  • Rocky Mountain Cancer Centers
    Verifizierte Postleitzahl
    Denver, Vereinigte Staaten· Rekrutierung
  • Hartford Krankenhaus
    Verifizierte Postleitzahl
    Hartford, Vereinigte Staaten· Rekrutierung
  • Yale New Haven Krankenhaus
    Verifizierte Postleitzahl
    New Haven, Vereinigte Staaten· Rekrutierung
  • Mayo Clinic Jacksonville
    Verifizierte Postleitzahl
    Jacksonville, Vereinigte Staaten· Rekrutierung
  • AdventHealth
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten· Rekrutierung
  • Piedmont Healthcare
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten· Rekrutierung
  • Winship Cancer Institute
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten· Rekrutierung
  • St Elizabeth Healthcare
    Verifizierte Postleitzahl
    Edgewood, United States· Rekrutierung
  • LSU Medical Center
    Verifizierte Postleitzahl
    New Orleans, Vereinigte Staaten· Rekrutierung
  • Henry Ford Hospital
    Verifizierte Postleitzahl
    Detroit, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What are GEP-NETs?

GEP-NETs are rare types of cancer that start in special cells in your gut or pancreas.

What does 'advanced' cancer mean in this study?

It means the cancer has spread from where it started or can't be fully removed by surgery.

What is Octreotide LAR?

Octreotide LAR is a medicine already used to treat GEP-NETs to help control tumour growth and symptoms.

Werde ich das neue Medikament auf jeden Fall bekommen?

Not necessarily. This study compares two groups, so you might get the new medicine alongside the standard treatment, or just the standard treatment.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes, you can choose to leave the study at any time, and this won't affect your medical care.

Wie Sie mehr erfahren können

Novartis Pharma

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.